Current Report Filing (8-k)
July 11 2017 - 8:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
:
July
11
, 2017
Kadmon Holdings
, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-
37841
|
|
27
-
3576929
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
450 East 29
th
Street
New York, NY
|
|
10016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (
212
) 3
08
-
6000
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item
8
.0
1
|
Other Events
.
|
On
July
11
, 2017,
Kadmon Holdings, Inc. (the “Company”)
issued a press release announcing
interim results from its ongoing Phase 2 clinical trial evaluating KD025, the Company’s Rho-associated coiled-coil kinase 2 inhibitor, in patients with previously treated chronic graft-versus-host
disease, a serious complication following allogeneic bone marrow or stem cell transplantation
.
The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
Exhibit No.
|
Description
|
99.1
|
Press Release, dated Ju
ly
11
, 2017, issued by Kadmon Holdings, Inc.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kadmon Holdings, Inc.
|
|
|
|
Date:
Ju
ly
11
, 201
7
|
|
|
|
/s/ Konstantin Poukalov
|
|
|
|
|
Konstantin Poukalov
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Apr 2023 to Apr 2024